Milestone Historical Balance Sheet
MIST Stock | USD 1.85 0.01 0.54% |
Trend analysis of Milestone Pharmaceuticals balance sheet accounts such as Total Stockholder Equity of 15.9 M provides information on Milestone Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Milestone Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Milestone Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Milestone Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Milestone Pharmaceuticals is a good buy for the upcoming year.
Milestone Pharmaceuticals Inventory |
|
Milestone |
About Milestone Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Milestone Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Milestone Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Milestone Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Milestone currently owns. An asset can also be divided into two categories, current and non-current.
Milestone Pharmaceuticals Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Milestone Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Milestone Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Milestone Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Milestone Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Most accounts from Milestone Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Milestone Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Milestone Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more information on how to buy Milestone Stock please use our How to Invest in Milestone Pharmaceuticals guide.At this time, Milestone Pharmaceuticals' Other Stockholder Equity is comparatively stable compared to the past year. Total Current Assets is likely to gain to about 102.2 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 63.9 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 1.9M | 2.9M | 2.2M | 2.3M | Total Assets | 119.8M | 74.5M | 75.2M | 103.5M |
Milestone Pharmaceuticals balance sheet Correlations
Click cells to compare fundamentals
Milestone Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Milestone Pharmaceuticals balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 123.4M | 150.0M | 119.8M | 74.5M | 75.2M | 103.5M | |
Other Current Liab | 3.6M | 1.0M | 1.9M | 2.9M | 2.2M | 2.3M | |
Total Current Liabilities | 8.3M | 6.2M | 6.8M | 6.1M | 7.2M | 6.4M | |
Total Stockholder Equity | 114.9M | 143.1M | 112.6M | 66.3M | 16.8M | 15.9M | |
Net Tangible Assets | 114.9M | 143.1M | 112.6M | 66.3M | 76.3M | 63.9M | |
Property Plant And Equipment Net | 929K | 1.3M | 926K | 2.7M | 2.2M | 1.3M | |
Net Debt | (119.3M) | (71.4M) | (113.4M) | (5.1M) | 38.0M | 39.9M | |
Retained Earnings | (113.5M) | (163.5M) | (206.3M) | (266.3M) | (326.0M) | (309.7M) | |
Accounts Payable | 4.4M | 4.6M | 4.4M | 2.3M | 4.0M | 3.6M | |
Cash | 119.8M | 72.3M | 114.1M | 7.6M | 13.8M | 13.1M | |
Non Current Assets Total | 929K | 1.3M | 926K | 2.7M | 2.2M | 1.3M | |
Non Currrent Assets Other | (929K) | (1.3M) | (926K) | (2.7M) | (2.4M) | (2.3M) | |
Cash And Short Term Investments | 119.8M | 142.3M | 114.1M | 64.6M | 66.0M | 97.4M | |
Net Receivables | 836K | 948K | 483K | 1.2M | 3.9M | 4.0M | |
Common Stock Total Equity | 2.0M | 226.2M | 251.7M | 251.9M | 289.7M | 161.3M | |
Common Stock Shares Outstanding | 15.8M | 29.3M | 41.8M | 42.5M | 43.0M | 34.5M | |
Liabilities And Stockholders Equity | 123.4M | 150.0M | 119.8M | 74.5M | 75.2M | 103.5M | |
Non Current Liabilities Total | 184K | 696K | 474K | 2.0M | 51.2M | 28.9M | |
Capital Surpluse | 2.7M | 3.8M | 8.5M | 15.7M | 18.1M | 19.0M | |
Inventory | (578K) | (725K) | (356K) | (331K) | (297.9K) | (312.8K) | |
Other Current Assets | 2.4M | 5.4M | 4.3M | 6.0M | 3.2M | 3.6M | |
Other Stockholder Equity | 3.8M | 8.5M | 15.7M | 24.4M | 33.8M | 35.5M | |
Total Liab | 8.5M | 6.9M | 7.2M | 8.1M | 58.5M | 33.5M | |
Net Invested Capital | 114.9M | 143.1M | 112.6M | 66.3M | 66.5M | 65.2M | |
Property Plant And Equipment Gross | 978K | 1.3M | 1.2M | 2.7M | 2.4M | 1.3M | |
Total Current Assets | 122.5M | 148.7M | 118.9M | 71.8M | 73.0M | 102.2M | |
Net Working Capital | 114.2M | 142.5M | 112.1M | 65.7M | 65.8M | 95.8M | |
Short Term Debt | 330K | 490K | 448K | 990K | 1.1M | 1.1M | |
Common Stock | 226.2M | 251.7M | 251.9M | 273.9M | 260.5M | 199.2M | |
Property Plant Equipment | 929K | 1.3M | 215K | 2.7M | 3.1M | 3.2M | |
Capital Stock | 226.2M | 251.7M | 251.9M | 273.9M | 260.5M | 232.1M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.